Doravirine 13C6
| Product Name | Doravirine 13C6 |
|---|---|
| Alternate Names | Doravirine Stable Isotopes, Stable Isotopes of Doravirine |
| CAT No. | CS-EK-02530 |
| CAS No. | 1338225-97-0 unlabeled |
| Category | Stable Isotopes |
| Stock | Enquire |
| Mol. Wt. | 431.7 g/mol |
| Mol. For. | C1113C6H11ClF3N5O3 |
| Hazardous | This is not a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Doravirine |
| Canonical Smiles | CN1C(=NNC1=O)CN2C=CC(=C(C2=O)OC3=CC(=CC(=C3)C#N)Cl)C(F)(F)F |
| InchIKey | ZIAOVIPSKUPPQW-UHFFFAOYSA-N |
| Inchl | InChI=1S/C17H11ClF3N5O3/c1-25-13(23-24-16(25)28)8-26-3-2-12(17(19,20)21)14(15(26)27)29-11-5-9(7-22)4-10(18)6-11/h2-6H,8H2,1H3,(H,24,28) |
| IUPAC | 3-chloro-5-[1-[(4-methyl-5-oxo-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)pyridin-3-yl]oxybenzonitrile |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
[13C6]-Doravirine is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of HIV-1 infection. It is a modified form of Doravirine, a drug approved by the FDA in 2018 for use in combination with other antiretroviral agents in adults with HIV-1 infection who have no prior antiretroviral treatment history.
[13C6]-Doravirine contains six carbon-13 isotopes, which can be used in pharmacokinetic studies to analyze drug metabolism, absorption, and distribution in the body. This is because the presence of carbon-13 isotopes allows for the differentiation of [13C6]-Doravirine from other forms of Doravirine in biological samples, such as blood or urine.
The chemical structure of [13C6]-Doravirine consists of a benzoxazole ring, a pyridine ring, and a cyclopropylamine moiety. It works by binding to the reverse transcriptase enzyme, which is essential for the replication of HIV-1, and inhibiting its activity. This prevents the virus from multiplying and spreading throughout the body, thus reducing the viral load and slowing the progression of HIV-1 infection.
Clinical trials have shown that [13C6]-Doravirine is effective in reducing HIV-1 viral load and increasing CD4 cell counts in patients with HIV-1 infection. It is typically administered orally, once daily, and can be taken with or without food. As with any medication, [13C6]-Doravirine may cause side effects, such as headache, nausea, and fatigue, and should only be used under the supervision of a healthcare provider.
Get an Instant Quote
Related Compounds
Doravirine 13C,d3 |